FDA Approves Breckenridge's Tofacitinib Citrate Application
The FDA has approved Breckenridge's application for Tofacitinib Citrate under ANDA209633.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / JAK Inhibitor
Asset: Breckenridge
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Breckenridge
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Breckenridge's Tofacitinib Citrate introduces a generic competitor in the JAK inhibitor market, which could significantly impact pricing and market share dynamics. Portfolio teams must evaluate the implications for their existing products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Breckenridge and competitors.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.